When a single drug commands an entire market category, the financial stakes become unusually clear. That is the situation with Columvi, Roche’s bispecific antibody therapy for aggressive lymphomas, which new projections suggest will more than double its current trajectory to surpass $2 billion in global sales by 2030.
The Business Research Company’s freshly released Columvi Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 offers a granular breakdown of where this growth is coming from, who is buying the treatment, and why one company controls the entire space.
LONDON, GREATER LONDON, UNITED KINGDOM, October 27, 2026 /EINPresswire.com/ — Columvi is carving out a notable niche in oncology therapeutics, riding the wave of targeted cancer treatments and an expanding pool of patients battling complex lymphomas. The coming years should bring substantial market growth, fueled by wider acceptance of bispecific antibody therapies and the outsized role hospital pharmacies play in administering these sophisticated drugs.
Also worth a look: IBM leads tiny slice of booming AI nuclear market set to hit $9B by 2030 and Starting Point wins platinum honor for doubling employer child care dollars.
Projections show the Columvi market will exceed $2 billion in value by 2030. That figure sits inside the much larger Oncology Drugs market, expected to reach roughly $441 billion that same year, meaning Columvi would represent about 0.5% of that sector. Measured against the entire Pharmaceuticals industry, projected at $2,496 billion by 2030, Columvi’s slice lands near 0.1%. The pace of expansion is the real headline: a compound annual growth rate (CAGR) of 44% through 2030 signals intense demand for next-generation hematology therapies.
Request A Free Sample Of The Columvi Market Report
https://thebusinessresearchcompany.com/sample_request?id=45398973&type=smp&name=Columvi%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
North America will be the engine of this growth. By 2030, the region is expected to dominate with a valuation of $0.87 billion, a sharp climb from $0.17 billion in 2025, reflecting a 39% CAGR. The reasons are familiar ones in oncology: expanded use of bispecific antibody treatments, a rising number of patients with relapsed or refractory diffuse large B-cell lymphoma, and better access to innovative cancer therapies. Aggressive clinical research from major pharmaceutical players and supportive regulatory approvals reinforce the region’s lead.
The United States will be the largest single market within North America, forecasted to reach $0.79 billion in 2030, up from $0.16 billion in 2025, growing at a 38% CAGR. Advanced oncology care infrastructure, widespread adoption of targeted immunotherapies, high healthcare spending on cancer drugs, and patient access programs for novel biologics all underpin this trajectory.
Access The Detailed Columvi Market Report Here
https://thebusinessresearchcompany.com/report/columvi-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Distribution follows a clear pattern. Hospital pharmacies will hold 93% of the market share by 2030, equivalent to $2 billion in value. That dominance is no accident: complex antibody therapies require supervised administration, oncology treatment centers are concentrated in hospitals, and patients with hematological malignancies are typically managed in specialized facilities. Specialty pharmacies are projected to add $0.1 billion and retail pharmacies $0.03 billion in value between 2025 and 2030, smaller but still growing pieces of the pie.
The market segments by indication into non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), and by mechanism into bispecific antibody therapeutics and targeted CD20-CD3 therapies.
Several forces are accelerating demand. The rising number of patients with relapsed or refractory diffuse large B-cell lymphoma is a primary driver, especially as aging populations and improved diagnostics expand the eligible patient pool. That alone contributes an estimated 1.5% annual growth in market value. Growing acceptance of bispecific antibody therapies adds roughly 1.0% growth annually, buoyed by physician confidence, robust clinical data, and regulatory endorsements. Increased investment in oncology research and clinical trials rounds out the picture, contributing about 0.8% annual growth through 2030.
Combination therapy is reshaping the treatment landscape. In April 2025, F. Hoffmann-La Roche Ltd. secured European Commission approval for Columvi combined with gemcitabine and oxaliplatin (GemOx) for patients who cannot undergo autologous stem cell transplantation. The CD20xCD3 bispecific action, paired with a fixed-duration and ready-to-use format, enhances immune targeting and treatment efficacy, broadening its use in advanced hematology care.
Roche’s market position is absolute. In 2025, the company stands as the sole supplier of Columvi (glofitamab), holding 100% of market share. That exclusivity stems from formidable scientific and regulatory barriers: complex biologic drug development, rigorous clinical validation, specialized production processes, and deep oncology expertise. Roche’s comprehensive hematology portfolio, global commercialization capabilities, and antibody engineering skills cement its leadership. As demand for targeted hematology treatments grows, Roche’s ongoing research and strategic regulatory efforts are expected to reinforce its dominance.
Roche’s strategy centers on advancing bispecific antibody platforms, expanding fixed-duration immunotherapy options, and pursuing cutting-edge clinical research. The company also focuses on securing regulatory approvals to widen global access and developing combination therapies for personalized cancer care.
Growth opportunities are concentrated in the pharmacy channel. Hospital, specialty, and retail pharmacies combined are forecasted to generate over $2.13 billion in new market value between 2025 and 2030, with hospital pharmacies contributing $2 billion of that total. This expansion reflects greater uptake of advanced lymphoma therapies, increased availability of targeted oncology drugs, and evolving distribution methods for biologic therapies.
The supply chain is well-established. Raw material suppliers include Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics Inc., Catalent Inc., and AGC Biologics. Major wholesalers and distributors include McKesson Corporation, Cencora Inc., Cardinal Health Inc., AmerisourceBergen Corporation, and Walgreens Boots Alliance Inc. End users span renowned institutions like Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, City of Hope, Massachusetts General Hospital, Johns Hopkins Hospital, and many others worldwide.
Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: marketing@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: This forecast underscores how a single innovative therapy can define an entire market segment, with Roche’s stranglehold on Columvi highlighting the high barriers to entry in biologic drug development. For investors and healthcare stakeholders, the 44% CAGR signals that targeted immunotherapy for lymphomas is not just a clinical breakthrough but a major commercial opportunity—one that will shape oncology spending and hospital distribution strategies for years to come.
